Fraud Probe Adds Legal Risk to PROCEPT BioRobotics' Already Fraught Turnaround

What happened

Levi & Korsinsky has commenced a fraud investigation into PROCEPT BioRobotics over potential securities law violations, focusing on CFO Kevin Waters' Q3 2025 earnings call statements reaffirming a $325.5 million revenue target and handpiece ASP of approximately $3,200. This comes as PRCT is in the midst of a commercial reset aimed at improving revenue quality, with recent handpiece ASP at ~$3,340 and targeting ~$3,500 for 2026 after a Q4 revenue miss. The investigation casts doubt on management's past assurances and amplifies existing credibility issues from the company's growth narrative reset, which has already led to reduced guidance and stock volatility. While PRCT's core thesis hinges on hitting procedure growth targets of 60k–64k U.S. procedures and gross margin expansion to ~65% in FY2026, the legal scrutiny introduces a new layer of uncertainty that could distract from execution. Investors now face a compounded risk profile where operational milestones must be achieved under the shadow of potential legal and regulatory fallout.

Implication

Investors must now weigh increased litigation risk against PRCT's operational turnaround, as any findings could lead to financial penalties or management changes that disrupt the commercial reset. The investigation may trigger additional regulatory scrutiny and shareholder lawsuits, further pressuring the stock price and liquidity in the near term. While the company's fundamental drivers—procedure growth, handpiece ASP trends, and gross margin improvement—remain critical, the legal overhang raises the cost of capital and could hinder capital allocation decisions. If the investigation drags on, it may erode trust in management's guidance, making it harder for PRCT to hit its FY2026 targets and achieve EBITDA positivity by 4Q26. Ultimately, resolution of this probe is necessary before investors can fully refocus on the operational scorecards, but until then, the stock faces heightened volatility and downside risk.

Thesis delta

The investment thesis for PRCT now incorporates significant legal and credibility risks from the fraud investigation, adding a new dimension to the already challenging operational turnaround. While the core thesis remains centered on achieving procedure growth and margin expansion targets, this development increases uncertainty around management's past statements and future accountability. Investors should adjust their risk assessment to include potential delays, distractions, or financial impacts from legal proceedings, which could affect the timeline for restoring credibility and reaching profitability.